🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsSide Effects & ManagementHeadaches on GLP-1 — my results so far

Headaches on GLP-1 — my results so far

TomFromTexas Sat, Apr 26, 2025 at 5:27 AM 40 replies 2,310 viewsPage 1 of 8
This thread is more than 13 months old. Information may be outdated. Consider searching for more recent discussions.
TomFromTexas
Member
645
2,890
May 2024
Austin, TX
Apr 26, 2025 at 5:27 AM#1

Nausea arrived on day two of each dose step, lasted about four days, and disappeared entirely by the second week — until the step where it did not.

What I am after is whether holding at a lower dose for longer actually reduces total side-effect burden or just spreads it out.

Practical detail welcome, however dull — the duller the better.

24 19PharmD_Rodriguez, julia.endo, JessicaM_2024 and 21 others
Reply Quote Save Share Report
PharmD_Rodriguez
Senior Member
3,456
14,567
Jan 2024
Miami, FL
Apr 26, 2025 at 6:06 AM#2

This one has a reasonably settled answer, so here it is. The practical protocol is dull and it works: smaller meals, stop eating at the first sign of fullness rather than at the end of the plate, drop the fat fraction of meals in the two days after dosing, and do not lie down straight after eating. Most of what people call unmanageable nausea is a meal-size and meal-composition problem interacting with a stomach that is emptying slowly.

23 18TinaHashiRN, robert_kc, dan_philly and 20 others
Reply Quote Save Share Report
tampaLisa73
Member
312
1,456
Oct 2024
Tampa, FL
Apr 26, 2025 at 6:45 AM#3
PharmD_Rodriguez said:
The practical protocol is dull and it works: smaller meals, stop eating at the first sign of fullness rather than at the end of the plate, drop the…

Agreed on adaptation, with a caveat: adaptation applies to gastric emptying and not to everything. If your problem is the aversion rather than the fullness, waiting does less, because the aversion is central and it is the mechanism working as intended.

Last edited: Apr 26, 2025 at 7:45 AM
22 17sarah_nash92, FitDadDave, RunnerRach and 19 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
amy_econ_NJ
Member
567
2,567
May 2024
Princeton, NJ
Apr 26, 2025 at 7:24 AM#4
TomFromTexas said:
Nausea arrived on day two of each dose step, lasted about four days, and disappeared entirely by the second week — until the step where it did not.

Same position here, arrived at the long way round. Holding genuinely reduces total burden rather than redistributing it, because the gastric-emptying component adapts. Receptor-level tachyphylaxis to the delayed-emptying effect develops over weeks while the central appetite effect persists, so the same dose is materially more comfortable at week six than at week two. A slower ladder therefore reaches the same dose with less cumulative nausea, not the same nausea spread thinner.

21 16gary_naperville, sean_dublin, hannah_MT and 18 others
Reply Quote Save Share Report
Dr.KarenChen
VIP Member
4,210
24,567
Nov 2023
San Francisco, CA
Apr 26, 2025 at 11:01 AM#5

Adding the clinical framing, because it changes how the question reads. The useful move here is to separate what is established from what is widely repeated. Those two sets overlap less than the confident tone of most write-ups suggests, and the second set is where nearly all the disagreement on this board comes from.

I would rather be corrected than agreed with, if it comes to it.

Last edited: Apr 26, 2025 at 5:01 PM
20 15sarah_nash92, FitDadDave, RunnerRach and 17 others
Reply Quote Save Share Report
1238

Similar Threads

Nausea incidence by dose tier — STEP and SURMOUNT meta-analysis16 replies
Constipation on GLP-1: pathophysiology and fiber protocol5 replies
Alopecia on GLP-1 — telogen effluvium differential diagnosis3 replies
Gallbladder disease risk — cholelithiasis data from clinical trials12 replies
Pancreatitis risk assessment — pooled safety analysis15 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register